GlassScriptPhysician profile
Marcella Pomeranz
NPI 1174064083
$13,505.85
in general payments reported to CMS, 2019-2025
29 companies · $7,641 in 2025
The $7,641 reported for 2025 was more than what 99% of Adult Health (Nurse Practitioner) providers received nationally (typical 2025 total: $182).
See the full distribution for Adult Health (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $606 · 2022: $1,589 · 2023: $2,120 · 2024: $1,550 · 2025: $7,641.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,668 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $5,475 · Education: $168.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,668.35 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $5,475.00 |
| Education | $168.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $4,233.74 | 2021-2025 | Tremfya, Stelara, Simponi |
| Ardelyx, INC. | $3,237.75 | 2023-2025 | Ibsrela |
| Abbvie INC. | $1,854.18 | 2021-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $610.07 | 2021-2025 | Xifaxan, Plenvu, Trulance |
| Genzyme Corporation | $552.57 | 2022-2025 | |
| Gilead Sciences, INC. | $416.15 | 2021-2024 | |
| Pfizer INC. | $283.45 | 2024-2025 | |
| Intra-Sana Laboratories | $281.72 | 2022-2024 | Reltone 200 Mg, Reltone 400 Mg, Glycate |
| Ironwood Pharmaceuticals, INC | $256.93 | 2022-2023 | Linzess |
| Lucid Diagnostics INC. | $255.45 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $242.19 | 2021-2024 | Entyvio, Eohilia, Vpriv |
| Aimmune Therapeutics, INC. | $197.17 | 2024-2025 | Zenpep, Vowst |
| Regeneron Healthcare Solutions, INC. | $166.45 | 2023-2025 | Dupixent |
| Merck Sharp & Dohme LLC | $148.62 | 2021-2024 | Dificid |
| Celltrion USA INC. | $130.64 | 2024-2025 | Vegzelma |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $119.98 | 2021-2025 | Watchman Flx |
| Braintree Laboratories, INC. | $108.07 | 2022 | |
| Redhill Biopharma INC. | $63.97 | 2021-2023 | |
| Qol Medical, LLC | $62.99 | 2021-2023 | Sucraid |
| Phathom Pharmaceuticals, INC. | $62.52 | 2024-2025 | Voquezna |
| Novo Nordisk INC | $41.01 | 2025 | Wegovy |
| Lilly USA, LLC | $33.60 | 2024 | Omvoh |
| Orphalan INC | $32.54 | 2025 | Cuvrior |
| Ipsen Biopharmaceuticals, INC | $26.25 | 2025 | Iqirvo |
| Ethicon US, LLC | $23.24 | 2021 | |
| Intercept Pharmaceuticals, INC. | $22.42 | 2022 | |
| Ferring Pharmaceuticals INC. | $17.29 | 2022 | |
| Celgene Corporation | $13.15 | 2023 | Zeposia |
| Nestle Healthcare Nutrition INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcella Pomeranz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.